Skip to main content

Lynx Announces New Head of Board of Directors

NEW YORK, Jan 5 – Lynx Therapeutics announced Friday that Craig Taylor has been named chairman of its board of directors.

Taylor, who has been director of Lynx since March 1994, will take over from Sam Eletr. Eletr is is leaving the board but is expected to stay on as a consultant to the company.

Taylor is president of Alloy Ventures, a venture capital firm that focuses on healthcare and information technology.

He is also a director of biotechnology company Pharmacyclics and a member of the board of directors of the National Venture Capital Association. He serves on the board of advisors of the MIT/Stanford Venture Laboratory.

Lynx of Hayward, Calif., develops Megaclone, a cloning procedure designed to discover gene expression patterns and genomic variations.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.